Characterization of hERG1 channel role in mouse colorectal carcinogenesis

Antonella Fiore¹,²,a, Laura Carraresi³,a, Angela Morabito¹,², Simone Polvani¹,²,⁵, Angelo Fortunato¹,², Elena Lastraioili¹,², Angelo P. Femina⁴, Emanuele De Lorenzo¹,⁶, Giovanna Caderni⁴ & Annarosa Arcangeli¹,²

¹ Department of Experimental and Clinical Medicine, Section of Internal Medicine and Oncology, University of Florence, Florence, Italy
² Istituto Toscana Tumori, Florence, Italy
³ LIGeMA, CeSAL, University of Florence, Florence, Italy
⁴ NEUROFARBA Department, Section of Pharmacology and Toxicology, Florence, Italy
⁵ Department of Biomedical Clinical and Experimental Sciences, University of Florence, Florence, Italy
⁶ Laboratory of Cancer Genetics and Gene Transfer, Core Research Laboratory, Istituto Toscana Tumori (CRL-ITT), AOU Careggi, Florence, Italy

Keywords
Apc<sup>min/+</sup> mice, azoxymethane, colorectal cancer, hERG1 channel, VEGF-A

Abstract
The human ether-à-go-go-related gene (hERG) K⁺ channel is upregulated in human colorectal cancer cells and primary samples. In this study, we examined the role of hERG1 in colorectal carcinogenesis using two mouse models: adenomatous polyposis coli (Apc<sup>min/+</sup>) and azoxymethane (AOM)-treated mice. Colonic polyps of Apc<sup>min/+</sup> mice overexpressed mERG1 and their formation was reverted by the hERG1 blocker E4031. AOM was applied to either hERG1-transgenic (TG) mice, which overexpress hERG1 in the mucosa of the large intestine, or wild-type mice. A significant increase of both mucin-depleted foci and polyps in the colon of hERG1-TG mice was detected. Both the intestine of TG mice and colonic polyps of Apc<sup>min/+</sup> mice showed an upregulation of phospho-Protein Kinase B (pAkt)/vascular endothelial growth factor (VEGF-A) and an increased angiogenesis, which were reverted by treatment with E4031. On the whole, this article assigns a relevant role to hERG1 in the process of in vivo colorectal carcinogenesis.

Introduction
Colorectal cancer (CRC) is one of the most common cancers among men and women in developed and industrialized countries [1]. Some of these tumors are hereditary [2, 3], while the majority are sporadic and linked to environmental factors [4].

In the last few decades, CRC progression was deciphered as an ordered multistep process, which depends on a series of genetic changes, involving the lack of tumor-suppressor and DNA-repair genes accompanied by the activation of oncogenes [5]. Each of these genetic aberrations leads to the accomplishment of specific morphological steps which lead the normal colonic mucosa to a true invasive carcinoma, through specific, ordered lesions [6].

Different mouse models, either genetically modified or chemically induced, have been generated to recapitulate the adenoma–carcinoma sequence that occurs in CRC,
with the aim of better defining the molecular basis of the disease and identifying novel drugs for treatment.

The genetic mouse model mostly used for this purpose is represented by adenomatous polyposis coli (Apc\textsuperscript{min/+}) mice, which carry a dominant heterozygous nonsense mutation at codon 850 of the mouse homologue of the human APC gene. Apc\textsuperscript{min/+} mice develop spontaneous multiple adenomas throughout the intestinal tract, mainly in the small intestine [7, 8].

Chemically induced colorectal carcinogenesis in rodents represents one of the most used animal models of CRC. Azoxymethane (AOM), a 1,2-dimethylhydrazine metabolite [9, 10], triggers colonic tumorigenesis in rodents [11], which almost totally reproduces the genetic and molecular alterations underlying CRC tumor progression [12], through a multistep process involving precancerous lesions such as mucin-depleted foci (MDF), adenomas, and cancers [10].

Among the genes whose expression is altered during the carcinogenic process, those encoding ion channel and transporters are acquiring a relevant role in the last few years [13]. In particular, K\textsuperscript{+} channels of the ether-à-go-go (EAG) family, mainly human ether-à-go-go-related gene (hERG1) [14] and EAG-1 [15], were found to be overexpressed in several types of human cancers [13, 16], including CRC [17–20]. Moreover, the genes encoding either channels were detected in the crypts of murine colon, after carcinogen treatment [18], and an upregulation of oncogenic K\textsuperscript{+} ion channels (BK, Elk1, and EAG) was detected in the colon of Apc\textsuperscript{min/+} mice [21].

We tested the \textit{in vivo} relevance of hERG1 channels during colorectal cancerogenesis by studying either Apc\textsuperscript{min/+} mice or AOM-treated mice. For this purpose, we produced hERG1-transgenic (TG) mice, which overexpress the hERG1 gene in the intestinal mucosa.

Materials and Methods

Mouse strains and production of TG mice

Fabp-Cre mice were purchased from National Cancer Institute – Mouse Models of Human Cancers Consortium (NCI-MMHCC) [22] and Apc\textsuperscript{min/+} mice were obtained from The Jackson Laboratory (stock number: 002020).

The 10-kb vector-free XbaI DNA fragment was micro-injected into the male pronucleus of fertilized eggs from FVB mice at LIGEMA, University of Florence, Italy, following standard procedures. TG mice were maintained in a heterozygous state in FVB background.

Animals were housed in plastic cages with a wire mesh providing isolation from the hygienic bed and were kept in temperature-, air-, and light-controlled conditions. They received food and water ad libitum. All experiments involving mice were performed in accordance with the criteria outlined in the Guide for the Care and Use of Laboratory Animals.

AOM treatment

Two-month old mice, 12 TG, and six controls, maintained in a C57BL6/FVB mixed background, received intraperitoneal (IP) injections of AOM (10 mg/kg body weight) once a week for 6 weeks; in addition, three controls and six TG mice were treated with physiologic solution. Three months after the last injection, all animals were killed to evaluate tumorigenesis. The entire gastrointestinal tract was removed for dissection and flushed with phosphate buffered saline (PBS) to remove intestinal content. The intestine was opened longitudinally and washed extensively with PBS. Colon–rectum was fixed in 4% formaldehyde made in PBS for 24 h, after which the tissues were stained with methylene blue (0.1% for 10 min). The number of polyps was determined under a dissecting microscope (20× power field).

Aberrant crypt foci (ACF) were determined according to Bird [23]. The same methylene blue-stained colons were then re-stained with high iron diamine Alcian blue (HID-AB), to identify MDF as described in Ref. [24]. MDF and ACF were identified under a microscope (400× magnification).

E4031 treatment of Apc\textsuperscript{min/+} and TG mice

Apc\textsuperscript{min/+} mice received daily for 3 months IP injections of 20 mg/kg E4031 (TOCRIS, Bristol, U.K.) dissolved in sterile water; control Apc\textsuperscript{min/+} mice received buffered saline only. After 3 months, animals were killed by cervical dislocation. The entire gastrointestinal tract was removed for dissection and flushed with PBS to remove intestinal content. The colon–rectum was opened longitudinally and washed extensively with PBS, fixed in 4% buffered formaldehyde for 24 h and then stained with methylene blue. The number of polyps was determined under a dissecting microscope (20× power field).

TG mice received daily for 14 days IP injections of 20 mg/kg E4031 (TOCRIS) dissolved in sterile water; control mice received buffered saline only. After 14 days, animals were killed by cervical dislocation. The entire gastrointestinal tract was removed for dissection and flushed with PBS to remove intestinal content. The organ was opened longitudinally and washed extensively with PBS, fixed in 4% buffered formaldehyde for 24 h and embedded in paraffin. Tissue sections (7 microns) were cut from blocks using a microtome (Leica RM2125/ RM2125RT, Nussloch, Germany). Immunohistochemistry (IHC) using antivascular endothelial growth factor
(VEGF-A) antibody was performed to evaluate differences between control and treated TG mice.

**RNA extraction, reverse transcription, and real-time quantitative PCR**

RNA was extracted from different tissues of wild-type (WT), TG, and Apcmin/+ mice using TRIzol reagent (Invitrogen, Groningen, the Netherlands) according to the manufacturer’s protocol. cDNA was obtained from 1 to 2 μg of RNA using 200 U reverse transcriptase Super-Script II (Invitrogen), plus 500 μmol/L each of deoxyribonucleotide triphosphate (dNTP) and 15 ng/μL of random primers, in a 20 μL final reaction volume, for 50 min at 42°C and 15 min at 70°C. cDNA synthesis was monitored by PCR with β-actin primers.

hERG1, mERG1, and myosin, heavy polypeptide 11, smooth muscle (myh11) mRNA quantification by real-time quantitative PCR (RT-qPCR) were performed on 2 μL of cDNA (diluted 1:4) using the 7500 Fast RT-PCR System and the SYBR Green Master Mix Kit (Applied Biosystems; Foster City, CA). The β-actin gene was used as RT-qPCR reference gene. The primer sequences for hERG1 were: 5’-CTCACCACCTGTACTTCA-3’ forward primer and 5’-GCTCCCCAAGATGCATT-3’ reverse primer; for β-actin: 5’-GGGTTTGAGGTCTCAA-3’ forward primer and 5’-GATCTGCAACACTTCTT-3’ reverse primer; for mERG1: 5’-GGACCCTGCTTACTGCCTCT-3’ forward primer and 5’-GGACGGGCATATAAGTTCAG-3’ reverse primer; and for myh11: 5’-CGACAGGCCTAGGATGGA-3’ forward primer and 5’-GCTCTCCAAAGATGTCATTC-3’ reverse primer. The relative gene expression was calculated applying the Pfaffl analysis method [25].

**Immunohistochemistry**

IHC was performed on 7-μm sections of tissues fixed in 4% formalin and embedded in paraffin, mounted on positively charged slides. After dewaxing and blocking endogenous peroxidases, sections were treated with proteinase K (Roche, Mannheim, Germany; 5 μg/mL in PBS) and UltraVBlock solution (LabVision, Fremont, CA) containing 0.1% Triton X-100, and then incubated with the following primary antibodies: anti-hERG1 monoclonal antibody [20] (dilution 1:200 in PBS-UltraVBlock), anti-VEGF-A (Santa Cruz Biotechnology, Santa Cruz, CA) (dilution 1:100 in PBS-UltraVBlock), anti-CD34 (Cedarlane, Burlington, NC) (dilution 1:100 in PBS-UltraVBlock) overnight at 4°C, and anti-phospho-Protein Kinase B (pAkt) (Santa Cruz Biotechnology) (dilution 1:100 in PBS-UltraVBlock) for 1 h at 37°C. For pAkt detection, antigen retrieval was carried out by heating slides in a microwave for 10 min at 600 W in citrate buffer (pH 6). For CD34 detection, antigen retrieval was carried out by irradiating the slides in a microwave for 20 min at 700 W in citrate buffer (pH 7.8).

Immunostaining was carried out using a commercially available kit (PicTure Plus kit; Zymed, San Francisco, CA). After extensively washing with PBS, color was developed by incubating the slides with the 3,3′-diamino-benzidine chromogen solution for 2–5 min or until acceptable color intensity had been reached. Slides were then counterstained with Mayer’s hematoxylin and mounted using Entellus mounting medium. Images were acquired on a Leica DM 4000B microscope with a Leica DFC 320 camera using Leica Win software (Leica Microsystems; Milan, Italy).

**Statistical analysis**

Data obtained from AOM-treated mice were reported as mean ± standard error of the mean (SEM) and analyzed by Mann–Whitney U test. A P-value <0.01 (*) was considered statistically significant.

Data obtained from vessel and total vascular area count of WT, TG, and Apcmin/+ mice were reported as mean ± SEM and analyzed by Mann–Whitney U test. P-values <0.05 and <0.01 were considered statistically significant.

Data obtained from VEGF-A and pAkt expressions were analyzed by Mann–Whitney U test. P-values <0.05 and <0.01 were considered statistically significant.

Data obtained from RT-qPCR experiments to detect mERG1 expression in TG and WT mice were reported as mean ± SEM and analyzed by Mann–Whitney U test (n: four WT mice and five TG mice). A P-value <0.05 (*) was considered statistically significant.

**Results**

**Role of hERG1 in colonic polyp development of Apcmin/+ mice**

We studied the role of hERG1 channels in CRC tumorigenesis, using Apcmin/+ mice as a model. On the basis of previous observations [26] indicating that the transcript encoding the murine homologue of the hERG1 gene, mERG1, was expressed in the colon of Apcmin/+ mice, we first determined mERG1 expression levels in various tracts of the intestine of such mice, by RT-qPCR.

We found that the colon and rectum of Apcmin/+ mice showed an increase in mERG1 expression, compared to that in WT mice. Such increase was more evident in colonic and rectal polyps, which spontaneously develop in these mice. Interestingly, mERG1 expression increased
along with the size of polyps (Fig. 1A). The mERG1 protein was also detected by IHC in colonic polyps of Apcmin/+ mice (Fig. 1B). Polyps displayed a high mERG1 expression in adenomatous epithelial cells (see arrows in Fig. 1B, right panel), while colonic samples of WT mice showed only a faint signal in the stroma (Fig. 1B, left panel).

When Apcmin/+ mice were treated with the specific hERG1 blocker E4031, daily for 3 months, such long-term mERG1 current inhibition [28–32], that, in agreement...
with a previous paper [33], did not lead to drug-induced torsades de pointes in E4031-treated mice, produced an impairment in colonic lesion development (Fig. 1C). No effects on the number of polyps in the small intestine were observed. Consistently, no overexpression of the mERG1 transcript was detected in the small intestine of Apcmin/+ compared to WT mice (Fig. 1A, left most bar).

**Effects of AOM treatment in hERG1 TG mice**

We then investigated the possible role of hERG1 in a chemically induced mouse model of CRC, utilizing AOM as carcinogen, and treating either WT or genetically modified mice, hERG1-TG mice, which overexpress the hERG1 gene in the intestinal mucosa.

The TG mouse model was developed by us, and the procedure we adopted is detailed in the supplementary information section. Briefly, the hERG1 cDNA, tagged with the myc epitope and a poly-histidine (His) flag at the protein C-terminal, was put under the control of the human β-actin minimal promoter, with an intercalated floxed reporter EGFP gene, which should block transgene transcription. However, hERG1-EGFPloxed mice expressed the hERG1 transcript both in the colon (Fig. 2A, white bars) and in the liver (Fig. S1D), even in the absence of Cre-mediated recombination (compare white and black bars in Fig. 2A). Hence, a transcriptional readthrough phenomenon occurred, and no further significant increase in hERG1 expression was triggered by Cre, for example after mating hERG1-EGFPloxed mice with Fabp-Cre mice. The latter mice express the Cre recombinase under the control of the Fabp promoter, hence in the whole digestive tract [22]. Therefore, hERG1-EGFPloxed mice, due to the transcriptional control exerted by the β-actin promoter, can be considered to overexpress the hERG1 transcript ubiquitously. Both the hERG1 transcript (Fig. 2A) and the hERG1 protein (Fig. 2B) were overexpressed in TG mice (either hERG1-EGFPloxed or hERG1-EGFPloxed-Cre) belonging to different TG lines (801, 883, and 886), compared to WT mice. In TG mice, hERG1 expression was strongly detectable in colonic epithelial cells and not limited to the stroma and myofibroblasts, as in WT mice. A slight, significant difference in mERG1 expression in TG compared to WT mice (1.88 ± 0.2 mERG1 expression in TG vs. 1.16 ± 0.1 mERG1 expression in WT; P = 0.03, Mann–Whitney U test) was detected, even if such mERG1 expression increment in TG mice resulted to be very minimal when compared to the artificial hERG1 expression. The generated TG mice did not show any apparent phenotype, even at old ages, and presented a normal life span.

Both TG and WT mice were treated with AOM (or physiologic saline), according to the schedule in Figure 3A, and the occurrence of colonic lesions was analyzed 3 months after the last injection. The macroscopic inspection of the large intestine of treated mice revealed, in the colon of AOM-treated TG mice, the presence of polyps that was, on the contrary, only barely detectable in WT mice (Fig. 3B). No lesions were observed in the large intestine of mice injected with physiologic saline. After staining the large intestine with methylene blue, the number of carcinogen-induced ACF, and after restaining with HID-AB, that of MDF was determined. A statistically significant increase in the number of MDF lesions in TG mice compared to WT mice was detected (Fig. 3B). The increase in MDF lesions paralleled the increased number
of polyps, as evidenced by macroscopic inspection. No significant difference was detected in the number of ACF between TG and WT mice.

**TG and Apc\textsuperscript{min/+} mice overexpress pAkt and VEGF-A in the epithelial lining of the large intestine**

Finally, we tried to decipher whether a common molecular mechanism could underlie the effect of hERG1 overexpression in the process of colorectal carcinogenesis, as evidenced in either the genetic (Apc\textsuperscript{min/+}) or chemical (AOM treated) mouse model. In different types of cancers, including CRC [20, 34, 35], hERG1 is functionally linked to the pathway that promotes the secretion of the VEGF-A, hence contributing to tumor angiogenesis [36].

On the basis of this assumption, we analyzed the expression of both pAkt (i.e., the kinase which regulates VEGF expression [37]) and VEGF-A in the large intestine of TG and in the mERG1-expressing polyps of Apc\textsuperscript{min/+} mice. A higher expression of both pAkt (Fig. 4A) and VEGF-A (Fig. 4B) was detected in the proximal colon and rectum of TG compared to WT mice. Similarly and consistent with previous reports [38, 39], a clear pAkt (Fig. 4E) and VEGF-A (Fig. 4F) immunostaining was detected in the polyps of Apc\textsuperscript{min/+} mice with significantly higher levels compared with control mice (Table 1). In both TG mice and Apc\textsuperscript{min/+} polyps, VEGF-A displayed a peculiar expression pattern, different from that observed in control mice. In fact, VEGF-A expression was not limited to the stroma, but was significantly present in the cells of the epithelial lining. The increased expression of VEGF-A in TG mice and Apc\textsuperscript{min/+} polyps was accompanied by a significant increase in angiogenesis, evaluated as microvessel density and total vascular area measured after staining with an anti-CD34 antibody (Fig. 4C and Table 2). Control mice showed smaller vessels mainly localized in the muscularis propria, while TG mice and Apc\textsuperscript{min/+} polyps were characterized by larger vessels with a less ordinate distribution.

Finally, we verified whether the upregulation of VEGF-A in TG mice was directly linked to a higher hERG1 activity and, hence, could be reverted by treatment with the hERG1 blocker E4031. Indeed, treatment of TG mice with E4031 for 2 weeks, led to a significant decrease in VEGF-A staining (Fig. 4D). This indicates that hERG1 channels are not only overexpressed in TG mice, and drive VEGF-A secretion and an increased angiogenesis but they are active and their activity is more or less directly responsible for the VEGF-A-enhanced production observed in these mice.
Discussion

Substantial evidence indicates that cancer can be partially attributed to ion channel malfunction. Numerous studies included hERG1 in the list of ion channels mis/overexpressed in cancer cells, where it plays the role of regulator of tumor cell proliferation and progression [40, 41]. In this article, we analyzed the role of hERG1 in colorectal carcinogenesis in vivo, using either genetic (Apc\textsuperscript{min/+} mice) or chemical (AOM treated) models of CRC. In both models, we found a relevant role of hERG1 channels, which could be traced back to a hERG1-dependent control of angiogenesis.

Colonic and rectal polyps, which spontaneously develop in Apc\textsuperscript{min/+} mice, showed an evident overexpression of the murine homologue of hERG1, mERG1 and the long-term treatment of Apc\textsuperscript{min/+} mice with the specific hERG1 blocker, E-4031, suppressed polyp formation in the large intestine. It is known that the main function of Apc is to degrade cytosolic levels of β-catenin, whose dysregulation is considered a major cause of tumor development. As previous studies from Carlos Munoz’s laboratory showed that β-catenin increased the hERG1 protein levels within the oocyte cell membrane [42], the increased hERG1 channel activity detected in the polyps of Apc\textsuperscript{min/+} mice could be attributed to the overexpression
of β-catenin, widely described in this animal model [43]. It is worth noting that, at difference from what happens in the small intestine, the loss of function of Apc is not sufficient per se to trigger the development of tumors in the colon, where adjunctive genetic events are required for the transition from microadenomas to macroscopic tumors to be accomplished [44]. Our data could suggest considering hERG1 as one factor which cooperates with Apc loss to trigger colorectal tumor progression.

This conclusion is further supported by data obtained in carcinogen-treated mice. In this case, in order to analyze the role of hERG1, we generated a TG mouse model overexpressing hERG1. On the bases of the construct we used, we expected to obtain a conditional hERG1-expressing mouse. On the contrary, due to a readthrough phenomenon, the mice we generated showed a ubiquitous expression of hERG1. Even when hERG1 was expressed at high levels, the hERG1-TG mice did not show any overt phenotype and presented a normal life span. Hence, hERG1 overexpression per se is not life-threatening and does not induce tumor development. Although hERG1-TG mice did not develop spontaneous tumor, they displayed an accelerated process of tumorigenesis, when treated with AOM, as witnessed by an increased number of preneoplastic lesions (mainly MDF) and polyps in the colon. It is worth noting that MDF, that is dysplastic lesions, characterized by a defective mucin production, are considered precursors of CRC both in humans [8, 45, 46] and in experimental models [24]. Our finding that the concomitant hERG1 and, probably transgene induced, mERG1 overexpression in the large intestine increases the number of AOM-induced MDF and polyps, strongly indicates that an upregulation of hERG1 accelerates the process of colorectal carcinogenesis, further stressing the role of hERG1 as a progression gene in CRC.

On the whole, the hERG1 gene can be considered a “tumor progression” gene, as it strongly cooperates with genetic (loss of the tumor-suppressor gene Apc) or environmental (chemical carcinogen) factors in triggering CRC progression.

Finally, we provided evidence that the role of hERG1 in CRC carcinogenesis can be traced back to its role in

| Table 1. VEGF-A and pAkt expressions in WT, TG, and Apcmin/+ mice evaluated by the percentage of positively immunostained cells. |
|---|---|---|---|---|---|---|
| | WT mucosa (FVB) | TG mucosa | WT mucosa (C57BL/6) | Apcmin/+ mucosa | Apcmin/+ polyps |
| | 3 months | 6 months | 3 months | 6 months | 6 months | 6 months |
| VEGF-A | 45% | 30% | 70% | 70% | 1% | 5% |
| | | NS | | | | 60% |
| pAkt | 25% | 10% | 60% | 60% | 10% | 10% |
| | | | | | | 30% |

WT, wild-type mice; TG, hERG1-transgenic mice; NS, nonsignificant. Statistical analysis: Mann-Whitney U test; n = 6 microscopic fields at 200× magnification.

*P = TG mice versus corresponding age-matched WT (FVB) mice.

**P = 6-month-old Apcmin/+ polyps versus 6-month-old WT mucosa (C57BL/6).

***P = 6-month-old Apcmin/+ polyps versus 6-month-old Apcmin/+ mucosa.

| Table 2. Vessel and total vascular area count in WT, TG, and Apcmin/+ mice. |
|---|---|---|---|---|---|---|
| | WT mucosa (FVB) | TG mucosa | WT mucosa (C57BL/6) | Apcmin/+ mucosa | Apcmin/+ polyps |
| | 3 months | 6 months | 3 months | 6 months | 6 months | 6 months |
| Number of vessels | 5.6 ± 0.7 | 3.6 ± 0.8 | 10.1 ± 1.1 | 8.6 ± 1.6 | 3.9 ± 0.3 | 4.7 ± 0.6 |
| | | | | | | | 15.9 ± 3.3 |
| Total vascular area (mm²/microscopic field) | 3.4 ± 0.6 | 2 ± 0.4 | 3.4 ± 0.6 | 5 ± 1.2 | 2.8 ± 0.6 | 3 ± 0.5 |
| | | | | | | | | 21.6 ± 7.5 |

WT, wild-type mice; TG, hERG1-transgenic mice; NS, nonsignificant. Data are reported as mean ± SEM; statistical analysis: Mann-Whitney U test; n = 12 microscopic fields at 200× magnification.

*P = TG mice versus corresponding age-matched WT (FVB) mice.

**P = 6-month-old Apcmin/+ polyps versus 6-month-old WT mucosa (C57BL/6).

***P = 6-month-old Apcmin/+ polyps versus 6-month-old Apcmin/+ mucosa.
the signalling pathways, which regulate VEGF-A secretion and neoangiogenesis. In CRC cells, hERG1 channels regulate pAkt, through the formation, on the plasma membrane, of a macromolecular complex between hERG1, the β1 integrin, and the p85 subunit of phosphatidylinositol-3-kinase, which leads to the activation of Akt (O. Crociani et al., pers. comm.). Consistently, we found an upregulation of pAkt and VEGF-A expression in both Apcmin/+ polyps and hERG1-TG mice. In the latter, the increased VEGF-A expression causes an increased angiogenesis, which was reverted by blocking hERG1 with a specific blocker. Hence, VEGF-A expression in vivo depends on hERG1 activity. Therefore, when hERG1 is aberrantly overexpressed, VEGF-A secretion and angiogenesis are concomitantly upregulated; through the increased angiogenesis, hERG1 activity may influence tumor development and progression.

Taken together, data reported in this article indicate a significant role of hERG1 in colorectal carcinogenesis in vivo, confirming indications, obtained in the human setting, that an early overexpression of the hERG1 gene marks those precancerous lesions of the upper gastrointestinal tract which undergo malignant progression [47]. Moreover, data here provided further stress the inclusion of hERG1 blockers in the treatment of CRC.

Acknowledgments
Grant Support: Associazione Italiana per la Ricerca sul Cancro (AIRC), Association for International Cancer Research (AICR), Istituto Toscano Tumori (ITT), Associazione Genitori Noi per Voi, and Ente Cassa di Risparmio di Firenze. We thank S. Aparicio (BC Cancer Agency, Vancouver, British Columbia, Canada) for the kind gifts of the β-actpA and the D11 loxP plasmids and S. Funghini (A.O.U. Meyer, Firenze) for technical support.

Conflict of Interest
All coauthors agree to the submission to IJC, agree with the content and presentation of the article, and declare that they have no conflict of interests.

References
1. Jemal, A., R. Siegel, J. Xu, and E. Ward. 2010. Cancer statistics, 2010. CA Cancer J. Clin. 60:277–300.
2. Lynch, H. T., T. Smyrk, and J. Lynch. 1997. An update of HNPCC (Lynch syndrome), Cancer Genet. Cytogenet. 93:84–99.
3. Jasperson, K. W., T. M. Tuohy, D. W. Neklason, and R. W. Burt. 2010. Hereditary and familial colon cancer. Gastroenterology 138:2044–2058.
4. Haggard, F. A., and R. P. Boushey. 2009. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin. Colon Rectal. Surg. 22:191–197.
5. Arnold, C. N., A. Goel, H. E. Blum, and C. R. Boland. 2005. Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 104:2035–2047.
6. Markowitz, S. D., and M. M. Bertagnolli. 2009. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 361:2449–2460.
7. Moser, A. R., H. C. Pitot, and W. F. Dove. 1990. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247:322–324.
8. Fodde, R., and R. Smits. 2001. Disease model: familial adenomatous polyposis. Trends Mol. Med. 7:369–373.
9. Neufert, C., C. Becker, and M. F. Neurath. 2007. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2:1998–2004.
10. Femia, A. P., and G. Caderni. 2008. Rodent models of colon carcinogenesis for the study of chemopreventive activity of natural products. Planta Med. 74:1602–1607.
11. Fiala, E. S. 1977. Investigations into the metabolism and mode of action of the colon carcinogens 1,2-dimethylhydrazine and azoxymethane. Cancer 40:2436–2445.
12. Nandan, M. O., and V. W. Yang. 2010. Genetic and chemical models of colorectal cancer in mice. Curr. Colorectal Cancer Rep. 6:51–59.
13. Arcangeli, A., O. Crociani, E. Lastraioli, A. Masi, S. Pillozzi, and A. Becchetti. 2009. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr. Med. Chem. 16:66–93.
14. Arcangeli, A., L. Bianchi, A. Becchetti, L. Faravelli, M. Coronello, E. Mini, et al. 1995. A novel inward-rectifying K+ current with a cell cycle dependence governs the resting potential of mammalian neuroblastoma cells. J. Physiol. 489:455–471.
15. Pardo, L. A., D. del Camino, A. Sanchez, F. Alves, A. Bruggemann, S. Beckh, et al. 1999. Oncogenic potential of EAG K(+) channels. EMBO J. 18:5340–5347.
16. Pardo, L. A., and W. Stuhmer. 2008. Eag1: an emerging oncolgical target. Cancer Res. 68:1611–1613.
17. Lastraioli, E., L. Guasti, O. Crociani, S. Polvani, G. Hofmann, H. Witchel, et al. 2004. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res. 64:606–611.
18. Ousingsawat, J., M. Spitzner, S. Puntheeranurak, L. Terracciano, L. Tornillo, L. Babendorf, et al. 2007. Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin. Cancer Res. 13:824–831.
19. Dolderer, J. H., H. Schuldes, H. Bockhorn, M. Altmannsberger, C. Lambers, D. von Zabern, et al. 2010. hERG1 gene expression as a specific tumor marker in colorectal tissues. Eur. J. Surg. Oncol. 36:72–77.

20. Lastraioli, E., L. Bencini, E. Bianchini, M. R. Romoli, O. Crociani, E. Giommoni, et al. 2012. hERG1 channels and glut-1 as independent prognostic indicators of worse outcome in stage I and II colorectal cancer: a pilot study. Tran. Oncol. 5:105–112.

21. Ousingsawat, J., M. Spitzner, R. Schreiber, and K. Kunzelmann. 2008. Upregulation of colonic ion channels in APCMin/+ mice. Pflugers Arch. 456:847–855.

22. Saam, J. R., and J. I. Gordon. 1999. Inducible gene knockouts in the small intestinal and colonic epithelium. J. Biol. Chem. 274:38071–38072.

23. Bird, R. P. 1987. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 37:147–151.

24. Caderni, G., A. P. Femia, A. Giannini, A. Favuzza, C. Luceri, M. Salvadori, et al. 2003. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res. 63:2388–2392.

25. Pfaffl, M. W., A. Tichopad, C. Ptgment, and T. P. Neuvians. 2004. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper – excel-based tool using pair-wise correlations. Biotechnol. Lett. 26:509–515.

26. Koehl, G. E., M. Spitzner, J. Ousingsawat, R. Schreiber, E. K. Geissler, and K. Kunzelmann. 2010. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min+)/mice. Oncogene 29:1553–1560.

27. Fortunato, A., L. Gasparoli, S. Falsini, B. Luca, and A. Arcangeli. In press. An analytical method for the quantification of hERG1 channel gene expression in human colorectal cancer. Diagn. Mol. Pathol.

28. London, B., M. C. Trudeau, K. P. Newton, A. K. Beyer, N. G. Copeland, D. J. Gilbert, et al. 1997. Two isoforms of the mouse ether-a-go-go-related gene coassemble to form channels with properties similar to the rapidly activating component of the cardiac delayed rectifier K+ current. Circ. Res. 81:870–878.

29. Babij, P., G. R. Askew, B. Nieuwenhuijsen, C. M. Su, T. R. Bridal, B. Jow, et al. 1998. Inhibition of cardiac delayed rectifier K+ current by overexpression of the long-QT syndrome HERG G628S mutation in transgenic mice. Circ. Res. 83:668–678.

30. Chiesa, N., B. Rosati, A. Arcangeli, M. Olivotto, and E. Wanke. 1997. A novel role for HERG K+ channels: spike-frequency adaptation. J. Physiol. 501:313–318.

31. Furlan, F., G. Taccola, M. Grandolfo, L. Guasti, A. Arcangeli, A. Nistri, et al. 2007. hERG conductance expression modulates the excitability of ventral horn GABAergic interneurons that control rhythmic oscillations in the developing mouse spinal cord. J. Neurosci. 27:919–928.

32. Pessia, M., I. Servettini, R. Panichi, L. Guasti, S. Grassi, A. Arcangeli, et al. 2008. ERG voltage-gated K+ channels regulate excitability and discharge dynamics of the medial vestibular nucleus neurons. J. Physiol. 586:4877–4890.

33. Pillozzi, S., M. Masselli, E. De Lorenzo, B. Accordi, E. Cilia, O. Crociani, et al. 2011. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 117:902–914.

34. Masi, A., A. Becchetti, R. Restano-Cassulini, S. Polvani, G. Hofmann, A. M. Buccoliero, et al. 2005. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br. J. Cancer 93:781–792.

35. Pillozzi, S., M. F. Brizzi, P. A. Bernabei, B. Bartolozzi, R. Caporale, V. Basile, et al. 2007. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110:1238–1250.

36. Arcangeli, A. 2011. Ion channels and transporters in cancer. 3. Ion channels in the tumor cell-microenvironment cross talk. Am. J. Physiol. Cell Physiol. 301:762–771.

37. Jiang, B. H., and L. Z. Liu. 2008. AKT signaling in regulating angiogenesis. Curr. Cancer Drug Targets 8:19–26.

38. Moran, L. E., D. H. Hunt, S. H. Javid, M. Redston, A. M. Carothers, and M. M. Bertagnolli. 2004. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6j-Min/+ mice. J. Biol. Chem. 279:43261–43272.

39. Spitzner, M., J. R. Martins, R. B. Soria, J. Ousingsawat, K. Scheidt, R. Schreiber, et al. 2008. Eag1 and Bestrophin 1 are up-regulated in fast-growing colonic cancer cells. J. Biol. Chem. 283:7421–7428.

40. Arcangeli, A. 2005. Expression and role of hERG channels in cancer cells. Novartis Found. Symp. 266:225–232.

41. Jehle, J., P. A. Schweizer, H. A. Katus, and D. Thomas. 2011. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis. 2:e193.

42. Munoz, C., A. Saxena, T. Pakladok, E. Bogatikov, J. Hamilton, B. Vogelstein, et al. 1994. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54:5523–5526.

43. Yamada, Y., and H. Mori. 2007. Multistep carcinogenesis of the colon in Apc(Min+)/+ mice. Cancer Sci. 98:6–10.
46. Yamada, Y., and H. Mori. 2003. Pre-cancerous lesions for colorectal cancers in rodents: a new concept. Carcinogenesis 24:1015–1019.
47. Lastraioli, E., A. Taddei, L. Messerini, C. E. Comin, M. Festini, M. Giannelli, et al. 2006. hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett’s esophagus. J. Cell. Physiol. 209:398–404.
48. Ng, S. Y., P. Gunning, R. Eddy, P. Ponte, J. Leavitt, T. Shows, et al. 1985. Evolution of the functional human beta-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol. Cell. Biol. 5:2720–2732.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. (A) Schematic representation of hERG1-myc conditional expression vector, including location of specific primers (1–7): 1–2 utilized for PCR genotyping specific for the hERG1-myc transgene; 3–4 used to detect transcriptional readthrough phenomenon, by amplification of a cDNA fragment spanning from the 3′ end of the egfp (primer 3) to the 5′ end of hERG1-myc (primer 4); 5–4 used to detect recombination in double transgenic mice; 6–7: utilized for hERG1-myc mRNA quantification by RT-qPCR. Restriction sites and the probe used in the Southern blot analysis are indicated. The beta-actin egfp hERG1 construct was assembled in pBluescript SK plasmid. The complete vector contains the 4.3 kb human beta-actin promoter plus intron [48] and the SV40 polyadenylation sequence; underscored: loxP sequence; bold and underscored: in liver of WT mice (white bar) and hERG1-EGFPFloxed mice (black bars) respectively from 801, 883, and 886 transgenic line is shown. Data are reported as mean ± SEM with normalization to WT liver. (E) A readthrough phenomenon was identified by the sequencing of a cDNA fragment, amplified with primer 3: 5′-ACACCCACTACCTGAGCAC-3′ and reverse 5′-CTACAGTGCTGTGACCAC-3′ primers (as indicated in [A]), spanning from the 3′ end of the egfp to the 5′ end of hERG1-myc of the construct. Bold: egfp sequence; cursive: polyA SV40 sequence; underscored: loxP sequence; bold and underscored: hERG1-myc sequence.

Figure S2. (A) hERG1-EGFPFloxed mice were mated with Fabp4kat-132Cre (Cre) mice. In the latter mice, the Cre recombinase should be expressed, although not exclusively, in the intestinal epithelium. Reverse transcription PCR showed mRNA expression of cre in different large intestine segment of hERG1-EGFPFloxed-Cre double transgenic (DT) mice. Amplification of cre was performed with Platinum® PCR SuperMix on 2 µL of cDNA derived from cecum, colon, and rectum of DT mice and with a specific primer pair: 5′-ACCAGCCAGCTATCACTCG-3′ and
5′-TTACATTGGTCAGCCACC-3′ and applying the following PCR conditions: denaturation at 94°C for 2 min, 35 cycles at 94°C for 1 min, 60°C for 1 min, 72°C for 1 min, and a final extension cycle at 72°C for 3 min. (B) The lack of a significant difference in hERG1 expression in hERG1-EGFPFloxed-Cre compared to hERG1-EGFPFloxed mice was also confirmed at the protein level: an immunohistochemical analysis was carried out in colon-rectum of hERG1-EGFPFloxed and DT mice, employing anti-Myc antibody (anti-myc 9E10; Santa Cruz Biotechnology), dilution 1:100 in PBS-UltraVBlock). No gross difference in the amount of Myc staining could be detected in DT compared to hERG1-EGFPFloxed mice: hERG1-EGFPFloxed as well as DT mice showed myc expression in the stroma and in the epithelial lining. (C) hERG1-EGFPFloxed-Cre double transgenic genomic DNA was tested by end-point PCR to verify the presence of Cre mediated recombination in mice. DNA extracted from colon and rectum of WT and hERG1-EGFPFloxed-Cre double transgenic mice was amplified with the 5′-AGGATCAGTCGAAATTCAAG-3′ and 4′-5′-ATGATGGTGTCCAGGAAG-3′ primers and applying the following PCR conditions: denaturation at 94°C for 2 min, 35 cycles at 94°C for 40 sec, 52°C for 1 min, 72°C for 1 min, and a final extension cycle at 72°C for 5 min. Such end point PCR failed to detect recombination in hERG1-EGFPFloxed-Cre double transgenic mice (data not shown); on the other hand, PCR analysis performed on genomic DNA extracted from tails of hERG1-EGFPFloxed-CMVCre mice revealed the correct transgene recombination in the presence of Cre.